Attorneys at Sidley Austin LLP examine the issue of drug price reporting rules under Medicaid and enforcement risks under the ...
Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 February 11, 2026 6:30 ...
BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical ...
New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional ...
An enterprise AI platform bringing decision-grade intelligence to regulated pharmaceutical operations This partnership ...
1d
Isosceles Pharmaceuticals Announces Acceptance of IPI201 for Phase I First-in-Human Clinical Trial
Novel intravenous anti-inflammatory candidate advances to Phase I evaluation to assess safety, tolerability, and ...
By Michael Erman SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U.S. drug pricing are looking to craft their own ...
State lawmakers are looking to fix the fallout of a billing mistake by the Virginia Department of Health (VDH) that triggered ...
New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation HOUSTON, TX / ACCES ...
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing ...
Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own ...
Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results